The effect of asymptomatic hyperuricemia on comorbidities and the possibility of its correction

V.I. Mazurov^1,2, R.A. Bashkinov^1,2, I.Z. Gaidukova^1,2, A.Yu. Fonturenko^1,2

¹I.I. Mechnikov North-Western State Medical University, St. Petersburg

²Clinical Rheumatology Hospital No. 25, St. Petersburg

Uric acid (UA) is the end product of purine metabolism. An increase in its serum level is defined as hyperuricemia (HU). In the absence of gouty arthritis signs, HU is considered asymptomatic. In recent decades, there has been a worldwide tendency to increase the prevalence of HU, which, as it turned out, has a wide range of effects on the progression of a large variety of pathologies with a therapeutic profile. Experimental and clinical studies have proven a high association of HU with various comorbidities. There are direct pathogenetic associations concerning elevated UA level with the occurrence and progression of cardiovascular pathology, damage to the musculoskeletal system, kidney disease and metabolic syndrome, which indicates that asymptomatic HU (aHU) is becoming a general therapeutic problem. That is why the conditions for the initiation of urate-lowering therapy (UST) in aHU are presented in the regulatory doc uments of the Russian Medical Society for Arterial Hypertension (RMSAH), IDEA and many other medical communities. At the same time, the viewpoints of specialists of various profiles remain ambiguous regarding the prescription of oral therapy in aHU, which raises the question concerning the expediency of preparing an interdisciplinary consensus on the patient management with aHU and comorbidities.

Keywords: uric acid, asymptomatic hyperuricemia, comorbidities, urate-lowering therapy.

For citation: Mazurov V.I., Bashkinov R.A., Gaidukova I.Z., Fonturenko A.Yu. The effect of asymptomatic hyperuricemia on comorbidities and the possibility of its correction. RMJ. 2021;7:24–30.